Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma

Multiple myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of neoplastic plasma cells. The use of proteasome inhibitors in the treatment of MM has led to significant improvements in outcomes. This article reviews data on the use of the two approved prote...

Descripción completa

Detalles Bibliográficos
Autores principales: Merin, Noah M., Kelly, Kevin R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381198/
https://www.ncbi.nlm.nih.gov/pubmed/25545164
http://dx.doi.org/10.3390/ph8010001
_version_ 1782364410289848320
author Merin, Noah M.
Kelly, Kevin R.
author_facet Merin, Noah M.
Kelly, Kevin R.
author_sort Merin, Noah M.
collection PubMed
description Multiple myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of neoplastic plasma cells. The use of proteasome inhibitors in the treatment of MM has led to significant improvements in outcomes. This article reviews data on the use of the two approved proteasome inhibitors (bortezomib and carlfilzomib), as well as newer agents under development. Emphasis is placed on the clinical use of proteasome inhibitors, including management of side effects and combination with other agents.
format Online
Article
Text
id pubmed-4381198
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-43811982015-04-30 Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma Merin, Noah M. Kelly, Kevin R. Pharmaceuticals (Basel) Review Multiple myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of neoplastic plasma cells. The use of proteasome inhibitors in the treatment of MM has led to significant improvements in outcomes. This article reviews data on the use of the two approved proteasome inhibitors (bortezomib and carlfilzomib), as well as newer agents under development. Emphasis is placed on the clinical use of proteasome inhibitors, including management of side effects and combination with other agents. MDPI 2014-12-24 /pmc/articles/PMC4381198/ /pubmed/25545164 http://dx.doi.org/10.3390/ph8010001 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Merin, Noah M.
Kelly, Kevin R.
Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
title Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
title_full Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
title_fullStr Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
title_full_unstemmed Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
title_short Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
title_sort clinical use of proteasome inhibitors in the treatment of multiple myeloma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381198/
https://www.ncbi.nlm.nih.gov/pubmed/25545164
http://dx.doi.org/10.3390/ph8010001
work_keys_str_mv AT merinnoahm clinicaluseofproteasomeinhibitorsinthetreatmentofmultiplemyeloma
AT kellykevinr clinicaluseofproteasomeinhibitorsinthetreatmentofmultiplemyeloma

Ejemplares similares